- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Life Science & Biotech
Product delays thwart $40M Roche purchase
March 12, 2011
J.K. WallDelays getting new diabetes meters into the U.S. market appear to have tripped up Roche Diagnostics Corp. on its way to acquiring
a key software vendor.
MorePurdue case highlights costs of defending intellectual property
March 12, 2011
J.K. WallA complicated legal case about trade secrets points up a down side to the success Indiana’s research universities have
had turning their research into revenue: Large legal bills can eat much of the money.
MoreLilly suffers another bruise from Novo
March 9, 2011
J.K. WallThe failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the
highly touted diabetes drug.
MoreLilly confident of FDA approval for Amyvid, Lechleiter says
March 9, 2011
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter said he’s confident of gaining U.S. regulatory approval for a drug to help identify
plaque in the brain associated with Alzheimer’s disease.
MoreDow Chemical moves toward engineered corn patent
March 1, 2011
Associated PressDow Chemical Co.'s agricultural division said it has taken the next step toward gaining international patent rights for
its new strain of genetically engineered corn that it says will help farmers battle a new strain of "super-weeds."
MoreUPDATE: Bioanalytical researcher opening lab in Indianapolis
March 1, 2011
Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the
workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of
a partnership.
MoreLilly looks to double pipeline size again
February 23, 2011
J.K. WallIndianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to
60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this
alternative pipeline.
MoreLilly's master plan for downtown (real estate)
February 19, 2011
Cory SchoutenAs Eli Lilly and Co. outsources work and sheds unnecessary properties, it is making moves with surplus real estate that could
establish the strongest physical connection between Lilly and downtown since the company was founded at Pearl and Meridian
streets 135 years ago.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreStruggling Lilly turns to antidepressant Cymbalta for lift
February 5, 2011
Greg AndrewsCymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition
arrives in 2013.
MoreEndocyte again changes terms of public offering
February 4, 2011
IBJ Staff and Bloomberg NewsThe West Lafayette-based biopharmaceutical company now is planning to offer at least 12.5 million shares, or 17 percent more
than previously announced, but at a lower price of $6 each.
MoreDow Agro's quarterly sales, profit climb
February 3, 2011
IBJ Staff and Associated PressIndianapolis-based Dow AgroSciences on Thursday reported record fourth-quarter revenue of $1.3 billion, up 19 percent from
the prior-year period.
MoreMarcadia may fetch up to $537 million in sale
February 2, 2011
J.K. WallThe December sale of Carmel-based Marcadia Biotech to Roche garnered at least $287 million—and as much as $537 million—for
the company’s owners and could lead the Marcadia management team to launch a firm using one of Marcadia’s experimental diabetes
medicines.
MoreMolecules are moneymakers for software firm Indigo BioSystems
January 29, 2011
Chris O'MalleyEli Lilly and Co. spin-off has landed new private investment and may double its work force this year.
MoreMarketing firm VMS plans growth, new jobs
January 28, 2011
IBJ StaffEvent-planning powerhouse VMS Inc. plans to invest more than $1.5 million to expand its Indianapolis life sciences marketing
operation and create as many as 102 jobs over the next four years, state officials said Friday morning.
MoreLife sciences to drive Purdue's next decade of building
January 26, 2011
J.K. WallOver the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center,
launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life
and Health Sciences Quadrangle next to Discovery Park.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
MoreEndocyte prices IPO stock
January 14, 2011
J.K. WallThe West Lafayette-based drug development firm intends to sell 6.15 million shares for $13 to $15 apiece. That would fetch
$80 million to $92 million.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreRoche back in court as partner looks to sell to competitor
January 12, 2011
J.K. WallRoche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving
word the company is speeding up plans to sell itself to Roche rival Alere Inc.
MoreDeal could give Lilly full diabetes deck
January 12, 2011
J.K. WallEli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy
that some consultants think is key to pharma companies’ futures.
MoreUPDATE: Analysts praise Lilly diabetes deal with Boehringer
January 11, 2011
J.K. WallThe deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with
five drugs and payments to be named later—but analysts and investors generally liked what they heard.
MoreAprimo sale may usher in 'new wave' of tech deals
January 8, 2011
Chris O'MalleyObservers say conditions are ripening for more deals like the recent $525 million sale of Aprimo Inc. in the months ahead—not
only among IT firms, but also among biotech companies here.
MoreRoche aims to prevent bidding war for software firm
January 7, 2011
J.K. WallThe Swiss company, which operates its North American business out of Indianapolis, filed a lawsuit late last month against
Virginia-based Medical Automation Systems Inc. for breaching the purchase agreement the companies signed back in October.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
So the Mayor adds another non value added layer to having a vehicle towed? Whereby the City Government RECIEVES AN ILLEGAL KICKBACK FROM A LGOISTICS COMPANY THAT SUBS THE WORK TO LOCAL TOW COMPANIES? What is the service the City performs for receiving the "tribute"? This is RICO!!!!! What a corrupt and unnecessary layer. What a dirtbag Mayor and his cronies.
Owner occupied housing. Clear enough?
So people think I am paranoid. It's from experience in dealing with puds requested by developers who make major donations themselves to representatives, have nice fund raisers for those running for office and hide through pac's. then there are the public relation firms. You will note some pr comments below. You there Clyde Lee? My opinion. Commercial along 421, great. Multifamily housing, terrible idea that will change the town. Senior condos or zero lot line homes west, great. I suggest keeping all entries to commercial areas at 421. All entries to owner occupied on sycamore. Will keep the traffic on sycamore down some. Two other things. You can't trust what will be there in 10 years. Steve builds quality stuff, but areas change over time. Look at the changes at the wall mart center at 86th and 421 over the last 10 years. Look at the apartments and neighborhoods behind St Vincent's. Raintree properties WILL decrease in value if commercial and multifamily goes in near. It has already been happening around the bridges area. The houses that have been sold recently are way below market. Several deals not closed due to the Illinois construction and the whole unsurety of the bridges. It's pretty simple, Zionsville will approve the whole thing because the city council has been groomed over a LONG period of time for this. I might even suggest some are in their position as a result of this.
Esta, do you have a dog in this fight? You seem to really want to knock anyone against this project. No, I didn't move to Indiana for the architecture. I moved here for that red barn in the field. The horses and fields of corn. A place that is NOT overdeveloped. There are plenty of nearby places in Indianapolis that could be REDEVELOPED instead.
RKW - OK, we get it, you're paranoid. The question is, are you paranoid enough? Greg - Yes, Pittman(s) is (are) at it again. They are developers, they build things. It's what they do. So when you go to work tomorrow, Greg, you're at it again too. Cliff - Really? You moved to Indiana for its progressive architecture? That's like moving to England for the cuisine. Zionsvillain - The house you moved to was once a field or woods. I'm willing to bet folks were upset when that ground was plowed under and a house was built. But I guess now that you are in, everything should stop? "My house was OK, but the next one is sprawl." SE Guy - Please don't paint us with such a wide brush. Most reasonable Zionsville residents welcome planned, measured development.